# US 2020/0347022 A1 · Novel azole derivatives as apelin receptor agonist

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0347022 A1
- Document ID: US20200347022A1
- Status: Published application
- Kind: A1
- Application number: 16/853,604
- Filed: 2020-04-20
- Published: 2020-11-05
- Earliest claimed: 2015-11-24
- Assignees: Sanford Burnham Prebys Medical Discovery Institute
- Applicants: Sanford Burnham Prebys Medical Discovery Institute
- Inventors: Takuya IKEDA; Yoshiyuki KOBAYASHI; Naoki MIYOSHI; Osamu SUZUKI; Takahiro NAGAYAMA; Takashi TSUJI; Layton H. SMITH; Anthony B. PINKERTON
- Web page: https://patentgrep.com/patent/US20200347022A1

## CPC

- C07D 249/12: Oxygen or sulfur atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/14: containing three or more hetero rings
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16C 20/50: Molecular design, e.g. of drugs
- G16C 99/00: Subject matter not provided for in other groups of this subclass
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE

## Abstract

The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X represents —N═ or —CH═, X2 represents —CH═ or —N═, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

A compound represented by formula (I), or a pharmacologically acceptable salt thereof:
wherein
X1 represents —CH═,
X2 represents —CH═ or —N═,
R1 and R2 each independently represent a C1 to C6 alkyl group, a C1 to C6 alkoxy group, or a halogeno group (the C1 to C6 alkyl group and the C1 to C6 alkoxy group are each optionally substituted by 1 to 3 fluoro groups),
R3 is a furyl group, a thienyl group, a pyridyl group, a phenyl group, a n-butyl group, or a cyclopentyl group (the furyl group, the thienyl group, the pyridyl group, and the phenyl group are each optionally substituted by 1 or 2 identical or different groups selected from a methyl group and a halogeno group); and
R4 is

### Claim 41 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein X2 is —CH═.

### Claim 42 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R1 and R2 are each independently a C1 to C6 alkoxy group or a C1 to C6 alkyl group.

### Claim 43 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R3 is a furyl group or a thienyl group (the furyl group or the thienyl group are each optionally substituted by 1 or 2 identical or different groups selected from a methyl group and a halogeno group).

### Claim 44 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R3 is a 5-methylfuran-2-yl group.

### Claim 45 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R4 is

### Claim 46 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R4 is

### Claim 47 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R4 is

### Claim 48 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R4 is

### Claim 49 (depends on 40)

The compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein R4 is

### Claim 50 (depends on 40)

A pharmaceutical composition comprising a compound according to claim 40, or a pharmacologically acceptable salt thereof, as an active ingredient.

### Claim 51 (depends on 40)

A method for treating a disease, comprising administering a pharmacologically effective amount of a compound according to claim 40, or a pharmacologically acceptable salt thereof.

### Claim 52 (depends on 51)

The method according to claim 51, wherein the disease comprises cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, valvular heart disease, metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, cardiac autonomic neuropathy, CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hypertension, systolic hypertension, vascular disease, vascular hypertrophy, vascular remodeling, vascular stiffness, atherosclerosis, peripheral arterial occlusive disease (PAOD), restenosis, thrombosis, vascular permeability disorder, cardiac, renal, or retinal disorder caused by ischemia, or cardiac, renal, or retinal disorder caused by reperfusion.

### Claim 53 (depends on 51)

The method according to claim 51, wherein the disease comprises cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, or valvular heart disease.

### Claim 54 (depends on 51)

The method according to claim 51, wherein the disease comprises metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, or cardiac autonomic neuropathy.

### Claim 55 (depends on 51)

The method according to claim 51, wherein the disease comprises CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hypertension, or systolic hypertension.

### Claim 56 (depends on 51)

The method according to claim 51, wherein the disease comprises vascular disease, vascular hypertrophy, vascular remodeling, vascular stiffness, atherosclerosis, peripheral arterial occlusive disease (PAOD), restenosis, thrombosis, vascular permeability disorder, cardiac, renal, or retinal disorder caused by ischemia, or cardiac, renal, or retinal disorder caused by reperfusion.

### Claim 57 (depends on 51)

The method according to claim 51, wherein the disease comprises pulmonary hypertension.

### Claim 58 (depends on 40)

A method for agonizing apelin receptor activity in a subject, comprising administering a compound according to claim 40, or a pharmacologically acceptable salt thereof, to a subject.

### Claim 59 (depends on 40)

A method for treating a disease or condition treatable by agonizing apelin receptor, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 40, or a pharmacologically acceptable salt thereof, wherein the disease or condition is cardiovascular disease, coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction, myocardial remodeling after cardiac surgery, valvular heart disease, metabolic disease, metabolic syndrome, insulin resistance, diabetes mellitus, diabetic late complications, diabetic macrovasculopathy, diabetic microvasculopathy, diabetic nephropathy, diabetic retinopathy, diabetic neuropathies, cardiac autonomic neuropathy, CNS-dependent disturbed fluid homeostasis, CNS-independent disturbed fluid homeostasis, acute renal failure, chronic renal failure, hypertension, pulmonary hypertension, portal hypertension, systolic hypertension, vascular disease, vascular hypertrophy, vascular remodeling, vascular stiffness, atherosclerosis, peripheral arterial occlusive disease (PAOD), restenosis, thrombosis, vascular permeability disorder, cardiac, renal, or retinal disorder caused by ischemia, or cardiac, renal, or retinal disorder caused by reperfusion.
